CURX CURX
Company Profile ↓Company Overview
CURX (CURX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.04.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -95.13% |
| 6 Months: | -35.17% |
| 3 Months: | -46.06% |
| 1 Month: | -13.74% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)38.07 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 97.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating Income | - | -44.20K | -93.30K | -137.45K | -57.66K | -951.33K | -3.18M |
| Net Income | -80.20K | -44.20K | -91.17K | -137.58K | -60.35K | -954.06K | -3.15M |
| Diluted EPS | - | -0.02 | -0.04 | -0.01 | 0.00 | -0.04 | -0.11 |
| R&D Expense | - | - | - | - | - | 677.47K | 2.26M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Income | -365.06K | -4.24M |
| Net Income | -361.51K | -4.23M |
| Diluted EPS | -0.03 | -0.17 |
| R&D Expense | - | 2.99M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | - | 517.93K | 11.58M |
| Total Equity | 60.09K | 503.36K | 11.22M |
| Cash & Equivalents | - | - | 5.00M |
| Total Liabilities | - | 14.57K | 361.04K |
| Current Liabilities | - | 14.57K | 137.03K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -555.58K | -10.48M |
| Financing Cash Flow | 630.10K | 15.31M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | -71.8% | -37.7% |
| ROCE % | -72.5% | -37.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CURX
Curanex Pharmaceuticals Inc Revenue Breakdown – NASDAQ:CURX - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE5CTEgzVG00Tm1lVEJ2RUdlSUNzSWJqM2pnOElxT2gzVHRic08yNnpMVm9nM1FybklTZEZZSU92OXp6QUE5bWN2dFRNMXMwWEJ5TVdpTUpfd1VyZzRlRDRIZHRWcFJUUDYzRjZmZXN4cElZYmpOejlF?oc=5" target="_blank">Curanex…
New plant-based ulcerative colitis drug targets FDA IND filing in 2026 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNcmRrYldLb0JzWWJPS3c0Wkl4aG9wNWNnS09mUnBEQ2hLcHJxOUlxYjBUR0FCOUg4aEExclZ1UDNKMnRxMHNpeTZyY0dWaGw0LXVtQzd5NGRWYW5WdVBmLVFpNFRVaGZfOGljeTBzZU1KMmRrMFVpSDI4dkxBZ1ZTMm5KN29GMFNfUWtQbG…
T-CURX buys Pantherna as the race for in vivo CAR-T gathers pace - European Biotechnology Magazine
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxQRVViV3ZTNnpsVTVxT1pZRkc0UlF1Q3pJTENGOUpndl9GcjNsWS14Ml84RUJUUHBCN1U5ZU5ySjVObWJ6NHE0cHNKTFFvM0x5Sk5pYzBnRmhxTWxpamw1NzFOMkMtM3lvV1BKVlhNMjREZjZtYXUxZjJKTVROdUMzZndR?oc=5" target=…
Curanex Pharmaceuticals Inc - TradingKey
<a href="https://news.google.com/rss/articles/CBMiZEFVX3lxTE9JZlR3UjA0Ulh4OGJid21vQWZaTVBLTVItWm9UZEphUEhIbnpaWUZFVnlKWkx6SmZ6OTBzaGZnVTlQS2JaN1puQXRndlVicFNqdURrQUlLVGluYW1JbVQ1RU1LOWc?oc=5" target="_blank">Curanex Pharmaceuticals Inc</a>&…
Curanex Pharmaceuticals (CURX) Slides 6% as Stock Tests Key Support at $0.18 - Insider Sentiment - po-news-eg.net
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQV3Y1ekdSWGwxWWRIaW1OaWM2R1pMM2trNm5KU1draF84UExiRUtzRU5ZbVZZbWRtZDZnZ1dLSXRyNFFLaXZPRGI5NzZOVUpzZVh3aXlROVdYaVZqdy1IRGZYS203d1dpOEVqemNkazJFY2ZNdENIdTRzN05pMUFUbm9kbkJlZi1kUXRTeD…
Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX) - Morningstar
<a href="https://news.google.com/rss/articles/CBMixwJBVV95cUxOWGhINmFzRUZNYWdfWnlJSGZoa05lMFdUMFV5TF9WbWlpTHNTUHJmOEpIV24tb3dJTWJ4Ql94QnhBME5aM1Z3N3VCbmJfM1FPUWlSVTdsUklTU3FiZjY0ajJiMGVmR1lsZVJpdnVtaDVSUzBlQjdPR1ZEcTdaYW1ZTmZPWjJQNGJlR2lTSF…
CURX — Frequently Asked Questions
What is the current share price of CURX?
As of 2026-08-05 17:25 PDT, CURX trades at $0.20 on NASDAQ/NYSE. Its 52-week range is $0.18 to $9.16.
What is the P/E ratio of CURX?
CURX trades at a trailing price-to-earnings (P/E) ratio of -1.18.
What is the return on equity (ROE) of CURX?
CURX has a return on equity (ROE) of -37.66%. Its return on capital employed (ROCE) is -37.04%.
Is CURX a good stock to buy?
This page provides a data-driven analysis of CURX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.